NuvaRing Faces Lawsuits for Faulty Birth Control Device
The dangerous prescription contraceptive device called NuvaRing has caused serious injuries to many women. Many lawsuits have been filed against the manufacturer of NuvaRing claiming a failure to adequately warn patients of the risks associated with the dangerous product.
The complaints against NuvaRing began in May 2007 and were filed asserting claims against Organon USA, Organon Pharmaceuticals USA, Inc., Organon International.
According to the Merck 2012 Annual Report, many of the cases are pending in federal multidistrict litigation (MDL). The venue for this MDL is in Missouri and in New Jersey state court. It’s reported that there are about 1,315 NuvaRing cases pending. 1,105 of those cases are pending in the MDL in the U.S. District Court in Missouri before Judge Rodney Sippel. 200 NuvaRing lawsuits are pending in Bergen County Superior Court of New Jersey before Judge Brian R. Martinotti. There are several other NuvaRing lawsuits pending in various other state courts.
The first NuvaRing MDL trial should take place in the summer of this year. Judge Martinotti ordered that both parties select nine trial pool cases to be prepared for trial.
The FDA released a study which found that NuvaRing can increase a woman’s risk of developing deep vein thrombosis by 56 percent in the first year. Blood clots can be very dangerous and can lead to a stroke or heart attack. A study in May 2012 published in the British Medical Journal found that there was a 6.5 time increased risk of blood clots in those patients using the NuvaRing.
If you or someone you loved has suffered a blood clot related injury after using the NuvaRing, we can help. Contact the attorneys of Childers, Schlueter & Smith for a free case evaluation and consultation. Our experienced attorneys will work closely with you and fight for the maximum compensation on your behalf.
This entry was posted
on Monday, May 20th, 2013 at 2:58 pm and is filed under FDA Alerts Blog, News Blog.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.